A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial

A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial

Background Myocardial metabolism plays an important role in maintaining cardiac function. Patients with dilated cardiomyopathy exhibit alterations in myocardial metabolism characterized by increased myocardial glucose metabolism. This study aimed to evaluate effects on myocardial metabolism of the a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sangyong Jo, Kyungil Park, Jae Hyuk Choi, Chang‐Bae Sohn, Jeonghwan Kim, Yong‐Seop Kwon, Su Hong Kim, Tae‐ho Park
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	myocardial metabolism olmesartan positron emission tomography valsartan
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.125.041406
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

Up-to-Date Aspects of Antihypertensive Therapy from the Viewpoint of Cardioand Nephroprotective Action: Olmesartan
by: A. G. Evdokimova, et al.
Published: (2020-05-01)

Atypical Rapid Onset of Olmesartan-Induced Enteropathy with Recurrence After Rechallenging
by: Lila Bekkai, et al.
Published: (2025-07-01)

A case report of olmesartan‐associated sprue‐like enteropathy: Diagnosis and healing confirmed by capsule endoscopy
by: Yoshiharu Yamaguchi, et al.
Published: (2023-04-01)

Angioprotection role in arterial hypertension treatment: focus on olmesartan
by: D. V. Nebieridze, et al.
Published: (2012-10-01)

Olmesartan‐Associated Enteropathy: An Uncommon Cause of Chronic Diarrhea
by: Ahmed Sayedahmed, et al.
Published: (2025-08-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

EFFECTS OF OLMESARTAN ON LOCAL AND REGIONAL RIGIDITY OF ARTERIES IN ISCHEMIC HEART DISEASE
by: I. B. Matrosova, et al.
Published: (2014-06-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study
by: Kl. O. Stumpe, et al.
Published: (1970-01-01)

ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION OF VALSARTAN AND VALSARTAN AND HYDROCHLOROTHIAZIDE COMBINATION IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Host–Guest Complexation of Olmesartan Medoxomil by Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Compatibility Study with Excipients
by: Dana Emilia Man, et al.
Published: (2024-12-01)

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
by: Narainrit Karuna, et al.
Published: (2025-05-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN AND RAMIPRILIN ELDERLY PATIENTS WITH MILD TO MODERATE SYSTOLIC AND DIASTOLICESSENTIAL HYPERTENSION
by: J‑M. Mallion, et al.
Published: (2012-06-01)

Clinical study on leflunomide combined with valsartan in the treatment of diabetic nephropathy proteinuria
by: WANG Li, et al.
Published: (2017-01-01)

DISSOLUTION PROFILE STUDIES OF BCS CLASS II DRUG VALSARTAN BY BIOWAIVER PROCEDURE
by: E. R. Brigas, et al.
Published: (2019-01-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
by: E. Malacco, et al.
Published: (2012-02-01)

Correction of Endothelial Dysfunction in Patients with Essential Hypertension when Using a Combination of Olmesartan/Lercanidipine and Zofenopril/Lercanidipine
by: O. V. Zimnitskaya, et al.
Published: (2016-11-01)

PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION
by: D. S. Kaskaeva, et al.
Published: (2017-03-01)

Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
by: I. N. Medvedev, et al.
Published: (2007-06-01)

ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01)

VALSARTAN IN EVERYDAY CLINICAL PRACTICE IN RUSSIA: ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects
by: Tian M, et al.
Published: (2025-01-01)

Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01)

Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet
by: Anjam H. Abdalla, et al.
Published: (2021-06-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
by: Alireza Arzhangzadeh, et al.
Published: (2025-05-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
by: J. M. Neutel, et al.
Published: (2011-04-01)

Effects of fluvastatin, valsartan, and their combination on endothelial function in patients with arterial hypertension and dyslipidemia
by: T. Sh. Mirilashvili, et al.
Published: (2009-08-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
by: Nobian Andre, et al.
Published: (2023-12-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

OPEN-LABEL RANDOMIZED CROSS-SECTIONAL STUDY OF CLINICAL EQUIVALENCE OF GENERIC AND ORIGINAL VALSARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION
by: V. B. Mychka, et al.
Published: (2015-02-01)

Valsartan pharmacokinetics in patients with controlled and uncontrolled arterial hypertension
by: S. V. Seleznev, et al.
Published: (2025-05-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)